| Logo | Name | Σ | Employees |
|---|---|---|---|
 |  Op2Lysis A New Hope for Hemorrhagic Stroke Op2Lysis develops new treatments for patients suffering from thrombosis at the cerebrovascular level, with an initial focus on the hemorrhagic form of stroke. Indeed, there is no currently approved and available therapeutic solution for these patients. The company develops its game-changing NANOp2Lysis platform, associating a breakthrough vectorisation technology, industrial know-how enabling clinical quality production, and preclinical expertise to propose predictive and translational models, a first in this field. O2L-001, the first product resulting from this technology, will soon enter regulatory toxicology with the aim of applying for clinical trial authorisation in patients in North … 34 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology | 6 | 8 |
 | MONCYTE Health Unique technology and novel data for personalized and optimal treatment of high cholesterol MONCYTE Health has a unique proprietary technology to quantify individual differences in cellular lipid uptake and storage which contribute to high blood cholesterol and the effectiveness of common lipid-lowering drugs. The readouts are derived from white blood cells, including monocytes, which play key roles in atherosclerotic plaque formation and inflammation, linking directly to cardiovascular risk. Precisely quantifying these individual differences enables personalized treatment strategies in combination with risk assessment which can help patients more effectively achieve optimal blood cholesterol levels faster, and thereby reduce the risk for … Type: Startup Activities: deeptech biotech Technologies: Data Analytics Synthetic Biology | 0 | 3 |
 | PepGen Better Technology. Better Delivery. Developing a new generation of disease-modifying therapies. Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic neuromuscular and neurological disorders. Biotechnology, Chemistry, Biology, Bioscience, Life sciences, and Therapeutics 436 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 1 | 89 |
 | uniQure Transforming the lives of patients through gene therapy uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases. aav, Huntington's disease, gene therapy, ALS, epilepsy, and Fabry disease 160 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology | 2 | 334 |
 | BioCardia, Inc. a leader in the development of comprehensive solutions for cardiovascular regenerative therapies We are a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. BioCardia is developing proprietary comprehensive biotherapeutic solutions for cardiovascular disease in its CardiAMPTM and CardiALLOTM therapies. Clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells. These programs are enabled by the Company's HelixTM transendocardial delivery systems and Morph® vascular access products, which are partnered to enable other promising biotherapeutic programs. 21 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 23 |